Literature DB >> 1923823

Characterization of a DNA binding activity in DNAse I hypersensitive site 4 of the human globin locus control region.

M Walters1, C Kim, R Gelinas.   

Abstract

A portion of the beta-globin Locus Control Region (LCR), which included DNAse I hypersensitive site 4 (HS4), was analyzed for its interactions with nuclear extracts and its contribution to LCR activity in a functional assay. In gel retardation assays, a short fragment from HS4 formed complexes with nuclear extracts from both erythroid and nonerythroid cells, and a core protected sequence 5'GACTGGC3' was revealed by DNAse I protection and methylation interference studies. This sequence resembles the binding sites of CCAAT-family members. Purified CP-2 but not CP-1 was shown to bind this HS4 sequence in a gel shift reaction, suggesting that the HS4 binding activity shares some sequence specificity with the CCAAT-factor family. Utilizing a transient expression assay in murine erythroleukemia cells, steady-state RNA levels were measured from pairs of LCR constructs linked to distinguishable beta-globin reporter genes. A short DNA fragment from HS4 which included the binding site for this novel binding activity accounted for most of the contribution to high level expression made by the entire HS4 region.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1923823      PMCID: PMC328903          DOI: 10.1093/nar/19.19.5385

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  59 in total

1.  Beta-globin locus activation regions: conservation of organization, structure, and function.

Authors:  Q L Li; B Zhou; P Powers; T Enver; G Stamatoyannopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

Review 2.  How eukaryotic transcriptional activators work.

Authors:  M Ptashne
Journal:  Nature       Date:  1988-10-20       Impact factor: 49.962

3.  Two tissue-specific factors bind the erythroid promoter of the human porphobilinogen deaminase gene.

Authors:  V Mignotte; L Wall; E deBoer; F Grosveld; P H Romeo
Journal:  Nucleic Acids Res       Date:  1989-01-11       Impact factor: 16.971

4.  The human beta-globin gene 3' enhancer contains multiple binding sites for an erythroid-specific protein.

Authors:  L Wall; E deBoer; F Grosveld
Journal:  Genes Dev       Date:  1988-09       Impact factor: 11.361

5.  Increased gamma-globin expression in a nondeletion HPFH mediated by an erythroid-specific DNA-binding factor.

Authors:  D I Martin; S F Tsai; S H Orkin
Journal:  Nature       Date:  1989-03-30       Impact factor: 49.962

6.  Purification of multiple erythroid cell proteins that bind the promoter of the alpha-globin gene.

Authors:  C G Kim; K M Barnhart; M Sheffery
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

7.  Developmental regulation of beta-globin gene switching.

Authors:  O R Choi; J D Engel
Journal:  Cell       Date:  1988-10-07       Impact factor: 41.582

8.  A dominant control region from the human beta-globin locus conferring integration site-independent gene expression.

Authors:  D Talbot; P Collis; M Antoniou; M Vidal; F Grosveld; D R Greaves
Journal:  Nature       Date:  1989-03-23       Impact factor: 49.962

9.  The beta-globin dominant control region activates homologous and heterologous promoters in a tissue-specific manner.

Authors:  G Blom van Assendelft; O Hanscombe; F Grosveld; D R Greaves
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

10.  Human CCAAT-binding proteins have heterologous subunits.

Authors:  L A Chodosh; A S Baldwin; R W Carthew; P A Sharp
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

View more
  1 in total

1.  Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure.

Authors:  P Leboulch; G M Huang; R K Humphries; Y H Oh; C J Eaves; D Y Tuan; I M London
Journal:  EMBO J       Date:  1994-07-01       Impact factor: 11.598

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.